Bayer news - the latest biotech news from Labiotech.eu

Improved vision with less eye injections for patients after primary endpoints met in trials

Liza Laws — Fri, 09 Sep 2022 14:01:09 +0000

The primary endpoints in two clinical trials investigating drug aflibercept 8 mg with 12 and 16-week dosing regimes, for patients with diabetic macular edema (DME) and wet age-related macular degeneration (wAMD), have been met. The trials, called PHOTON in DME and PULSAR in wAMD, both showed the dosing regimens achieved non-inferiority in vision gains compared […]

The post Improved vision with less eye injections for patients after primary endpoints met in trials appeared first on Labiotech.eu.

© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Clearance given to clinical trial with potential to change course of brain disease

Liza Laws — Wed, 24 Aug 2022 18:27:54 +0000

A trial to look at gene therapy, BV-01, for Huntington’s Disease has been given the go ahead to take place in France and has ‘the potential to change the course of the devastating disease. Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, received clearance for the phase 1/2 […]

The post Clearance given to clinical trial with potential to change course of brain disease appeared first on Labiotech.eu.

Ginkgo acquires Zymergen for $300M and picks up Bayer facility for $83M

Jim Cornall — Tue, 26 Jul 2022 08:21:36 +0000

U.S. cell programming company Ginkgo Bioworks has signed definitive agreements to acquire two teams and technologies. The deals are with Bayer and Zymergen. Bayer transaction The company confirmed the previously announced transaction with Bayer to expand Ginkgo’s platform capabilities in agricultural biologicals. Ginkgo will acquire Bayer’s 175,000-square-foot West Sacramento Biologics Research & Development site, team, […]

The post Ginkgo acquires Zymergen for $300M and picks up Bayer facility for $83M appeared first on Labiotech.eu.

Expansion into Europe for BlueRock Therapeutics

Jim Cornall — Fri, 10 Jun 2022 15:50:00 +0000

BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, has established a new site for cell therapy innovation on Bayer’s campus in Berlin, Germany. The move comes as part of the company’s growth strategy. A multidisciplinary BlueRock team will be set up during 2022 to provide clinical development and operational […]

The post Expansion into Europe for BlueRock Therapeutics appeared first on Labiotech.eu.

Big Pharma Strikes Megadeals In Targeted Protein Degradation

Anita Chakraverty — Fri, 12 Nov 2021 10:52:36 +0000

With many targeted protein degraders hitting the clinic, lucrative collaborations and acquisitions are being signed between biotech startups and big pharma in this upcoming area. Novartis, Pfizer, and Bayer have all negotiated billion Euro deals this year with smaller biotechs including Dunad Therapeutics, Arvinas, and Vividion Therapeutics. The big pharma companies aim to gain a […]

The post Big Pharma Strikes Megadeals In Targeted Protein Degradation appeared first on Labiotech.eu.

Farxiga’s Approval Fuels Chronic Kidney Disease Comeback

Jonathan Smith — Tue, 08 Jun 2021 15:51:45 +0000

Until this year, there were no effective treatments for chronic kidney disease. However, the recent approval of AstraZeneca’s Farxiga alongside clinical breakthroughs and advances in precision medicine are causing the field to resurge. The last several months have seen big pharma companies scoring wins against chronic kidney disease (CKD). This condition involves gradual, irreversible kidney […]

The post Farxiga’s Approval Fuels Chronic Kidney Disease Comeback appeared first on Labiotech.eu.

Women’s Health Gains Traction as Bayer Pays €736M for UK Firm

Jonathan Smith — Tue, 18 Aug 2020 14:15:32 +0000

Bayer’s recent €736M ($875M) acquisition of KaNDy Therapeutics could herald growing investor interest in women’s health – a historically neglected field in the biotech and pharma industry. Through this deal, Bayer has snapped up KaNDy Therapeutics’ first-in-class drug for treating hot flashes and night sweats, which often occur during the menopause. In a phase IIb […]

The post Women’s Health Gains Traction as Bayer Pays €736M for UK Firm appeared first on Labiotech.eu.

Meiogenix, Bayer Team Up to Boost Genetic Diversity in Crop Breeding

External Contributor — Mon, 10 Feb 2020 16:39:08 +0000

Bayer and the French biotech company Meiogenix will work together to advance the development of Meiogenix’s plant breeding and genome editing technologies with the hope of improving food crops for farmers. For many years, the only way to improve characteristics such as yield and nutritional value of crops was through selective breeding, which can be […]

The post Meiogenix, Bayer Team Up to Boost Genetic Diversity in Crop Breeding appeared first on Labiotech.eu.

Bayer Launches Israeli Company to Develop Viruses Against Crop Disease

Jonathan Smith — Thu, 11 Jul 2019 12:25:57 +0000

Bayer is backing the launch of the Israeli biotech Ecophage, which will develop environmentally friendly crop disease treatments based on bacteria-hunting viruses called bacteriophages. Bacteria can cause a range of diseases in crops, including blight and root rot. These infections are often hard to control because they happen faster than fungal infections. The treatments used […]

The post Bayer Launches Israeli Company to Develop Viruses Against Crop Disease appeared first on Labiotech.eu.

The Race to Get CRISPR to the Clinic: Hope Versus Hype

Helen Albert — Thu, 28 Jun 2018 07:00:32 +0000

In 2016, German pharma giant Bayer took a bold step and decided to partner with CRISPR Therapeutics to form a company that could join the race to be first into the clinic with a CRISPR therapy. Peter Nell worked at Bayer for many years and was one of the founding team of Casebia Therapeutics. Now […]

The post The Race to Get CRISPR to the Clinic: Hope Versus Hype appeared first on Labiotech.eu.

“Have the guts to follow your instincts”: Top CEO Talks About His Time in Biotech

Alexander Burik — Wed, 20 Jun 2018 10:27:40 +0000

Some careers take on an international scope and span the breadth of big players in the pharmaceutical industry and small biotech startups. David Ebsworth, Chairman at Verona Pharma, can count his professional journey among these and gave us the inside scoop on the successes and challenges he faced, his perspective on European biotech, and advice to […]

The post “Have the guts to follow your instincts”: Top CEO Talks About His Time in Biotech appeared first on Labiotech.eu.

After settling lawsuit with Bayer, Cellectis spin-off launches €41M follow-on offering

Helen Albert — Thu, 17 May 2018 10:05:58 +0000

Cellectis spin-off Calyxt has launched a €41M follow-on round after settling the lawsuit it recently brought against Bayer CropScience, for breach of a license agreement for access to patents for its TALEN technology. The French biotech Cellectis owns 79.1% of the ag biotech’s outstanding shares. Cellectis is well-known for its gene editing tool TALEN. However, while it focuses […]

The post After settling lawsuit with Bayer, Cellectis spin-off launches €41M follow-on offering appeared first on Labiotech.eu.

CRISPR/Cas9: Could the Gene Editing Technology be the Future of Drug Discovery?

Melanie De Almeida — Tue, 06 Feb 2018 10:03:05 +0000

The emergence of CRISPR/Cas9 technologies has enabled almost unlimited gene editing opportunities. Not only could it be used as a therapeutic tool, the genome editing tool could kickstart a revolution in drug discovery. To date, much of the attention on CRISPR/Cas9, which stands for clustered regularly interspaced short palindromic repeats, has revolved around its potential as […]

The post CRISPR/Cas9: Could the Gene Editing Technology be the Future of Drug Discovery? appeared first on Labiotech.eu.

Bayer Launches Plant Microbiome Biotech with a Huge €84M Series A

Clara Rodríguez Fernández — Fri, 15 Sep 2017 10:33:20 +0000

Bayer and Ginkgo Bioworks are launching a new company that will develop new technologies for sustainable agriculture by engineering the plant microbiome. With the microbiome already gaining traction in the therapeutics field, Bayer has decided to take it to agriculture. In partnership with US synthetic biology upstart Ginkgo Bioworks, the German giant is creating a new […]

The post Bayer Launches Plant Microbiome Biotech with a Huge €84M Series A appeared first on Labiotech.eu.

Bayer and Evotec Extend their Endometriosis Partnership

Clara Rodríguez Fernández — Mon, 24 Jul 2017 10:06:16 +0000

Bayer and Evotec have decided to extend their partnership for the development of endometriosis drugs now that their second candidate has made it to Phase I. Bayer and Evotec have announced today that a second compound derived from their endometriosis partnership has made it to clinical trials. The team has decided to extend the partnership […]

The post Bayer and Evotec Extend their Endometriosis Partnership appeared first on Labiotech.eu.

Novartis Tops Ophthalmology Blockbuster Eylea in Phase III Trials

Melanie De Almeida — Tue, 20 Jun 2017 14:35:21 +0000

Bayer’s and Regeneron’s blockbuster Eylea could be facing serious competition, as Novartis boasts with positive Phase III results for AMD. Novartis has been struggling on the age-related macular degeneration (AMD) market since its Roche-partnered VEGF-A inhibitor Lucentis was outperformed by Eylea from Bayer and Regeneron, which required a less-frequent dosing schedule and was placed at a lower […]

The post Novartis Tops Ophthalmology Blockbuster Eylea in Phase III Trials appeared first on Labiotech.eu.

Where to Find the Perfect Mix of International and German Biotechs? Berlin!

External Contributor — Thu, 15 Jun 2017 08:00:37 +0000

Germany’s capital city Berlin is the perfect meeting place for international and German biotech companies. See here why the city has become a hotspot for life sciences research institutions and businesses! “Berlin! Berlin! We’re going to Berlin!” It might be a phrase usually sung by football fans, but maybe it’s time to have it chanted by other […]

The post Where to Find the Perfect Mix of International and German Biotechs? Berlin! appeared first on Labiotech.eu.

What’s Berlin’s Secret to Success in Biotech & Digital Health?

External Contributor — Thu, 16 Mar 2017 07:00:09 +0000

Berlin is a creative crossroads not just for arts but also life science. A variety of players in academia, industry, and startups make the ecosystem blossom. To those who know Berlin as a creative hub, it might come as a surprise that life science is one of the city’s industrial pillars. The German capital region […]

The post What’s Berlin’s Secret to Success in Biotech & Digital Health? appeared first on Labiotech.eu.

Which European Blockbusters Topped the Charts in 2016?

Melanie De Almeida — Wed, 08 Mar 2017 12:48:57 +0000

Blockbuster drugs are raking in billions each year in sales. Let’s have a look at the top 7 European best-seller drugs of 2016 and what their competition has to say. Not surprisingly, the top 3 best-selling drugs in Europe are biologicals, which are revolutionizing the treatment possibilities for a range of conditions, from cancer to chronic diseases. But with the increasing […]

The post Which European Blockbusters Topped the Charts in 2016? appeared first on Labiotech.eu.

The Largest Deals, Fundraising and Exits of 2016 in European Biotech

Clara Rodríguez Fernández — Mon, 26 Dec 2016 07:00:06 +0000

Curious about which technologies have attracted the most cash in biotech finance this year? Here’s a list of the most impressive cash movements of 2016 in Europe. Believe it or not, 2016 has been the worst year for biotech finance in a decade. The political scene has become unfavorable for British biotech after Brexit, and the uncertainty raised by […]

The post The Largest Deals, Fundraising and Exits of 2016 in European Biotech appeared first on Labiotech.eu.